SBL
DXCM icon

Sargent Bickham Lagudis’s DexCom DXCM Stock Holding History

Sargent Bickham Lagudis’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12
Closed -$1K – 1063
2022
Q3 		$1K Sell
12
-12
-50% -$1.02K ﹤0.01% 924
2022
Q2 		$2K Buy
24
+12
+100% +$1.09K ﹤0.01% 915
2022
Q1 		$2K Hold
12
– – ﹤0.01% 883
2021
Q4 		$2K Buy
+12
New +$1.72K ﹤0.01% 878
2021
Q2 		– Sell
-112
Closed -$10K – 941
2021
Q1 		$10K Sell
112
-88
-44% -$8.26K ﹤0.01% 689
2020
Q4 		$18K Buy
+200
New +$17.9K ﹤0.01% 569

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sargent Bickham Lagudis's DXCM Position: Q4 2022 in Review

Sargent Bickham Lagudis sold out of DexCom (DXCM) in Q4 2022, closing a stake of 12 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in DXCM in Q4 2020 and held it in 6 quarters. The position peaked at $18K in Q4 2020. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2022.

  • Sargent Bickham Lagudis reported no remaining DexCom position as of Q4 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 12 DexCom shares in Q4 2022, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in DexCom in Q4 2020 and held it in 6 quarters.
  • Sargent Bickham Lagudis's DexCom position peaked at $18K in Q4 2020.
  • 920 funds tracked by Wall St. Rank held DexCom as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.